Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2389 in Steatotic Liver Disease and Advanced Fibrosis
NCT07610837Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2026
- Primary completion
- Jul 2027
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of AZD2389 in steatotic liver disease (MASLD) and Liver Fibrosis (LF) (2 arms), sponsored by AstraZeneca. Primary endpoints: Enhanced Liver Fibrosis at 24 weeks, Adverse Events at Day 197 and 8 more. Started May 2026; status: recruiting.
02
Drugs
AZD2389
03
Conditions
steatotic liver disease (MASLD)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT07610837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610837.